Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
22.83
+0.23 (+1.02%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
99
100
Next >
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
August 05, 2024
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...
Via
Benzinga
Exposures
COVID-19
Investing $100,000 in These 7 High-Yield Dividend Stocks Could Generate Over $7,000 in Annual Passive Income
August 04, 2024
Making passive income should be easy with these great stocks.
Via
The Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
August 03, 2024
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost.
Via
The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
August 03, 2024
Lilly's revenue gains have helped its stock to roar higher.
Via
The Motley Fool
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
August 02, 2024
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from...
Via
Benzinga
Exposures
COVID-19
Is Pfizer Winning Its $43 Billion Bet?
August 02, 2024
Pfizer's efforts are starting to bear fruit.
Via
The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
July 31, 2024
Via
Benzinga
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
August 02, 2024
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours.
Via
InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Subdued Blue-Chip Stocks That Will Reward Patient Investors
August 02, 2024
These are the blue-chip stocks to buy as they represent companies with strong fundamentals and growth acceleration possibility.
Via
InvestorPlace
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.
Via
The Motley Fool
Pfizer $PFE Beats Earnings Estimates
July 30, 2024
Pfizer $PFE Beats Earnings Estimates and Raises Full-Year Outlook Amid Cost-Cutting Measures
Via
Chartmill
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
August 01, 2024
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment.
Via
InvestorPlace
Phio Pharmaceuticals Announces New Chief Financial Officer
August 01, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Topics
Initial Public Offering
Exposures
Securities Market
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
August 01, 2024
Moderna delivered nearly double the sales analysts expected in the second quarter.
Via
Investor's Business Daily
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
August 01, 2024
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth.
Via
The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
August 01, 2024
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term.
Via
The Motley Fool
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
August 01, 2024
Pfizer shares have advanced 20% over the past three months.
Via
The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
July 31, 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals.
Via
InvestorPlace
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
July 31, 2024
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating expectations. Analysts highlight Pfizer's robust portfolio, effective...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Pfizer (PFE) Q2 2024 Earnings Call Transcript
July 30, 2024
PFE earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
July 30, 2024
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2024
Via
Benzinga
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
July 30, 2024
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them. This...
Via
Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
July 30, 2024
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...
Via
Benzinga
Exposures
COVID-19
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Dow Jumps 200 Points; Pfizer Earnings Top Views
July 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
July 30, 2024
Pfizer reports Q2 adjusted EPS of $0.60, beating the $0.46 consensus. Sales reached $13.28 billion, driven by acquired products and new launches, despite a decline in Comirnaty. Updated 2024 revenue...
Via
Benzinga
Exposures
COVID-19
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
July 30, 2024
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks."
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.